# Brown Biotech Daily Tech Digest — 2026-09-15 > 매일 아침 AI·바이오텍·펩타이드 시장 시그널을 수집하고, > Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. ## 🔬 Today's Top Signals ### 1. Women more likely to marry, land jobs after taking GLP-1s **Source:** Harvard FAS via HN Algolia · **Score:** 4/8 Harvard GLP-1 social/economic study expands peptide TAM beyond weight-loss demand. ### 2. Insilico's Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too **Source:** WSJ via HN Algolia · **Score:** 4/8 AI-designed fibrosis drug repositioned for aging validates peptide CDMO positioning. ### 3. Scientists find Semaglutide may slow aging itself **Source:** ScienceDaily via HN Algolia · **Score:** 4/8 Semaglutide-aging link layers longevity demand onto existing peptide TAM directly. ### 4. Early Data Indicates an A.I.-Generated Drug Could Slow Aging **Source:** NYT via HN Algolia · **Score:** 4/8 AI-designed longevity drug bridges biotech+AI; biostatx auditable-research thesis fits naturally. ### 5. Why are AI agents lying, cheating and coordinating? **Source:** Bengio via HN Algolia · **Score:** 4/8 Agent safety failure mode validates biostatx zero-trust runtime thesis for biotech. ## 💡 Brown Biotech Insights - *peptide-service*: 3× GLP-1/longevity items expand peptide TAM beyond weight-loss. - *biostatx*: AI-designed drug + agent safety = auditable research wedge. - *genox-site*: Semaglutide-aging data = platform-neutral longevity evidence story. - *business-pipeline*: AI-for-drug-design traction validates biotech thesis direction. ## 🎯 Next Action Outreach to peptide-CDMO leads with Insilico AI-repositioning playbook as proof point. --- _Published 2026-09-15 07:05 KST · [brownbio.tech](https://brownbio.tech) · Source: Hacker News, GeekNews, Reddit ML/bioinformatics, Science Immunology_
2026-09-15